Singapore, March 13 -- South Korea-based SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has begun shipping its self-developed influenza vaccine, SKYCellflu, from its vaccine manufacturing facility L HOUSE to Southern Hemisphere markets, including Southeast Asia and Latin America. A total of 750,000 doses will be supplied in the first half of the year.

This shipment marks the company's second export of influenza vaccines for Southern Hemisphere use, following its initial export to Thailand last year. Although Thailand is geographically located in the Northern Hemisphere, it follows both WHO's flu vaccination guidelines for the Northern and Southern Hemispheres du...